Medical News
Addiction
Allergies
Alternative Medicine
Asthma
Cancer
Cardiology
Chiropractic
Dental
Dermatology
Diabetes
Emergency
Family Medicine
General
Geriatrics
Hospitals
Infectious Diseases
Internal Medicine
Managed Care / HMO
Medical Products
Mental Health
Neurology
Nursing
Nutrition
OB / GYN
Pediatrics
Pharmaceuticals
Physical Therapy
Plastic Surgery
Psychology
Radiology / Imaging
Research
Sports Medicine
Surgery
Vision

XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies

XTELL has launched a commercial biorepository service, bioVAULT, which stores, manages and processes large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development.

Athens, OH (PRWEB) August 5, 2008 -- XTELL announced today the launch of its commercialized, independent biorepository service stemming from its collaborations with The Ohio University Endocrine Diseases Biorepository. XTELL's "bioVAULT" service will provide storage of biological samples derived from human/animal serum and tissues with 100% guaranteed confidentiality. BioVAULT will allow clinicians and researchers alike to facilitate and link patient/family medical history.

XTELL is a biotechnology company founded in 2001, dedicated to both the development of biological specimen storage and electronic medical record software.

A large part of XTELL's success has been from a direct partnership with Ohio University's Diabetes Center in creating a biorepository designed specifically for fundamental and translational research. Samples include DNA, RNA, and protein extracted from blood serum in patients living in a region of the United States with a high prevalence of diabetes and endocrine-related disease. XTELL has developed one of the most advanced diabetes biorepositories of its kind, with a state-of-the-art collection and storage facility.

BioVAULT is now capable of storing, managing and processing large numbers of biological specimens. BioVAULT is targeting scientific and pharmaceutical companies investigating new drug and diagnostic development, as well as universities. "Biorepositories are now critical in understanding the molecular mechanisms of disease and for the development of new therapeutics, " said Anthony Schwartz, President of XTELL.

XTELL is privately held and located in Athens, Ohio and is seeking new investors for building up its infrastructure as well as to secure its long-term growth.

Additional information is available at: http://www.xtell.com

Contact:

XTELL

Anthony Schwartz

President

Telephone: 1.800.314.0735

E-mail: info @ xtellnetworks.com

###

Simillar Articles

Precision Stability Storage Increases Storage Capacity by 120%
Precision Stability Storage (PSS) is a cGMP facility containing various chambers and rooms that have been mapped and validated for pharmaceutical stability storage and BioTech stability storage....
Pharmaceutical/BioTech Stability Storage Facility Opens
Precision Stability Storage opened a new facility for the pharmaceutical/biotech industry, providing state-of-the-art offsite stability storage rooms and chambers.
Precision Stability Storage Adds 30°C / 75% to its Range of Available Storage Conditions
Precision Stability Storage announces 30°C / 75% RH stability storage availability at its Wilson, NC facility.
Parameter Generation & Control Becomes Preferred Provider for Precision Stability Storage
Parameter Generation & Control, Inc. will be the preferred provider of stability storage rooms and controls to Precision Stability Storage, LLC. These stability rooms and chambers are utilized by...
Precision Stability Storage Expanding into New England
Precision Stability Storage, LLC (PSS) announced today that it is finalizing plans to open a new facility in New England. The expansion is expected to be made in a few stages over the next several...
Home Terms of Use Privacy Policy Contact Us